Citations

Clear

350 citation(s) found for "Stevens, V".

Angiotensin II in the Evolution of Experimental Heart Failure
Luchner, Andreas, Stevens, Tracy L., Borgeson, Daniel D., Redfield, Margaret M. , Bailey, Jane E., Sandberg, Sharon M., Heublein, Denise M., Burnett, John C.

Mayo Clinic

Hypertension | June 12, 2012 | Volume: 28 | Issue: 3 | Pages: 472-477

10.1161/01.hyp.28.3.472 | PMID 8794835 Get It

Although angiotensin II (Ang II) has been implicated in the pathophysiology of congestive heart failure, its temporal and regional changes during the development and progression of the disease are poorly defined. Our objective was to assess circulating, renal, cardiac, and vascular Ang II in a canine model of rapid ventricular pacing–induced heart failure that evolves from early left ventricular dysfunction to overt congestive heart failure. Ang II was measured by radioimmunoassay with low cross-reactivity to other angiotensins. Control, early left ventricular dysfunction, and overt congestive heart failure dogs were studied. Early left ventricular dysfunction was characterized by impaired cardiac function, cardiac enlargement, preserved renal perfusion pressure, maintained urinary sodium excretion, and normal plasma renin activity. Overt congestive heart failure was characterized by further impaired cardiac function and cardiac enlargement, reduced renal perfusion pressure, urinary sodium retention, and increased plasma renin activity and plasma Ang II. In early left ventricular dysfunction dogs, renal cortical, renal medullary, ventricular, and aortic Ang II were unchanged, and atrial Ang II was decreased. In overt congestive heart failure dogs, Ang II was increased in the kidney and heart compared with normal dogs and in all tissues compared with early left ventricular dysfunction dogs. The greatest increase in tissue Ang II occurred in the renal medulla. We conclude that early increases in local renal, myocardial, and vascular Ang II do not occur in this model of early left ventricular dysfunction and may even be suppressed. In contrast, increased myocardial and particularly renal Ang II in association with increased circulating Ang II are hallmarks of overt experimental congestive heart failure. These studies provide new insights into the temporal and regional alterations in Ang II during the progression of experimental congestive heart failure.
Modulation of exogenous and endogenous atrial natriuretic peptide by a receptor inhibitor.
Stevens, Tracy L., Wei, Chao , Aahrus, Lawrence L., Heublein, D. M., Kinoshita, Masanao , Matsuda, Y, Burnett, J. C., Heublein, Denise M.

Mayo Clinic

Hypertension | June 12, 2012 | Volume: 23 | Issue: 5 | Pages: 613-618

10.1161/01.hyp.23.5.613 | PMID 8175170 Get It

Atrial natriuretic peptide is an important peptide hormone of cardiac origin that functions to regulate cardiac preload via the regulation of sodium excretion. This natriuretic action occurs through activation of the particulate guanylyl cyclase-linked natriuretic peptide-A receptor. HS-142-1 is a newly discovered antagonist of the natriuretic peptide-A receptor that permits insight into the functional role of atrial natriuretic peptide in cardiorenal homeostasis. The first objective of this study was to define for the first time the intrarenal action of HS-142-1 on exogenous atrial natriuretic peptide-mediated natriuresis in anesthetized normal dogs. In group 1 (n = 6), which received intravenous atrial natriuretic peptide at 100 ng/kg per minute, intrarenal HS-142-1 (0.5 mg/kg bolus) attenuated atrial natriuretic peptide-induced increases in glomerular filtration rate, urine flow, sodium excretion, and renal cyclic GMP generation and decreases in distal tubular sodium reabsorption. The second objective was to determine whether endogenous atrial natriuretic peptide participates in the regulation of basal sodium excretion. In group 2 (n = 6), intrarenal HS-142-1 alone decreased both absolute and fractional sodium excretion and renal cyclic GMP generation and increased distal tubular sodium reabsorption. These studies demonstrate that HS-142-1 markedly attenuates exogenous atrial natriuretic peptide-mediated natriuresis via enhancement of distal tubular reabsorption and blunting of increases in glomerular filtration rate. Second, the current studies support a functional role for endogenous atrial natriuretic peptide in the regulation of basal sodium excretion.
Practice parameter: Immunotherapy for Guillain–Barré syndrome
Hughes, Richard AC , Barohn, Richard J., Benson, Estelle, Cornblath, David R., Hahn, Angelika F., Meythaler, Jay M. , Miller, Robert G. , Sladky, John T., Stevens, J. Clarke, Wijdicks, Eelco F. M.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 61 | Issue: 6 | Pages: 736-740

10.1212/wnl.61.6.736 | PMID 14504313 Get It

Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review) [RETIRED]
Petersen, Ronald C. , Stevens, J E , Tangalos, Eric G., DeKosky, Steven T. , Ganguli, Mary , Cummings, Jeffrey L.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 56 | Issue: 9 | Pages: 1133-1142

10.1212/wnl.56.9.1133 | PMID 11342677 Get It

The frequency of carpal tunnel syndrome in computer users at a medical facility
Stevens, J. Clarke, Witt, John C., Smith, Benn E., Weaver, Amy L.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 56 | Issue: 11 | Pages: 1568-1570

10.1212/wnl.56.11.1568 | PMID 11402117 Get It

A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis
Noseworthy, John H., O’Brien, Peter C. , Petterson, Tanya M. , Weis, Jennifer A., Stevens, L., Peterson, W. K., Sneve, D., Cross, Shelley A., Leavitt, Jacqueline A., Auger, Raymond G., Weinshenker, Brian G. , Wingerchuk, D. M., Dodick, David W. , Rodriguez, Moses , Weinshenker, Brian G

Mayo Clinic

Neurology | May 13, 2012 | Volume: 56 | Issue: 11 | Pages: 1514-1522

10.1212/wnl.56.11.1514 | PMID 11402108 Get It

Limitations of quantitative sensory testing when patients are biased toward a bad outcome
Dyck, Peter James , Kesserwani, Hassan, Melanson, Michel, Ochoa, Juan José Arana, Shy, Michael E. , Suarez, G. A., O’Brien, Peter C. , Kennedy, William R. , Stevens, Julie , Shy, Michael E

Mayo Clinic

Neurology | May 13, 2012 | Volume: 50 | Issue: 5 | Pages: 1213-1213

10.1212/wnl.50.5.1213 | PMID 9595965 Get It

Seronegativity for type 1 antineuronal nuclear antibodies ('anti‐Hu') in subacute sensory neuronopathy patients without cancer
Chalk, Colin , Lennon, Vanda A. , Stevens, J. Clarke, Windebank, Anthony J.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 43 | Issue: 11 | Pages: 2209-2209

10.1212/wnl.43.11.2209 | PMID 8232930 Get It

Post‐lumbar puncture headaches
Kuntz, Karen M. , Kokmen, E., Stevens, John C., Offord, K. P., Ho, Mei-Mei, Miller, Pamela K.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 42 | Issue: 10 | Pages: 1884-1884

10.1212/wnl.42.10.1884 | PMID 1407567 Get It

Trigeminal sensory neuropathy associated with connective tissue diseases
Hagen, Neil A. , Stevens, J. Clarke, Michet, Clement J.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 40 | Issue: 6 | Pages: 891-891

10.1212/wnl.40.6.891 | PMID 2161090 Get It